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ABSTRACT
Objective: The objective of the study is to assess the prevalence of depression among patients with cardiovascular disease and its association with 
the use of β-blockers and statins.
Methods: This is a prospective observational study conducted at a corporate hospital, Hyderabad, Telangana, India, for a period of 6 months. 250 
cardiac patients above 16 years are included in the study. The required data are collected from the patients through direct interview using standard 
questionnaires and also from patients’ respective case sheets. The acquired data are evaluated based on the standard questionnaires Patient Health 
Questionnaire-9 (PHQ-9) and Beck Depression Inventory-II (BDI-II) scales; used to diagnose the severity of depression in cardiac patients.
Results: Prevalence of minor to major depressive symptoms according to BDI-II was found to be 17.2%. Prevalence of minor to major depressive 
symptoms according to PHQ-9 was found to be 19.2%. Among male patients, 13% showed depressive symptoms, whereas among female patients 
25% showed depressive symptoms. Among the patients coadministering beta-blockers and statins, 15% were depressed according to BDI-II, and 
16% were depressed according to PHQ-9 at visit. After 1 month (first follow-up), the percentage increased by 8% (for BDI-II)-12% (for PHQ-9) and 
remains almost the same at the second follow-up. As per BDI-II and PHQ-9 scores, the percentage of patients with minor to major depression among 
the patients using only beta-blockers decreased significantly from the time of visit to the second follow-up. The percentage of patients with minor to 
major depression among the patients using only statins increased significantly from the time of visit to second follow-up.
Conclusion: Prevalence of minor to major depression according to BDI-II was found to be 17%, whereas according to PHQ-9, it was found to be 20% 
in patients with cardiovascular disease. Cardiovascular diseases have been more prevalent in men than in women, whereas depressive symptoms 
have been more prevalent in women than in men. Patients using only β-blockers showed a decrease in symptoms of depression. Whereas statins have 
shown to increase the chances of depression slightly which is often negligible, atorvastatin was associated with a higher level of depression when 
compared to rosuvastatin. Controversies still exist that statins decrease risk of depression.
Keywords: β-Blockers, Depression, Statins, Cardiovascular diseases, Psychological aspects, Screening.
INTRODUCTION
Depression and heart diseases go hand in hand and are among the most 
disabling diseases we face [1]. Cardiovascular disease (CVD) patients 
with depression have a worse outcome than those patients without it [2]. 
The drugs commonly used by CVD patients, i.e. lipophilic beta-blockers 
and statins are said to have a relationship with respect to increased risk 
of depressive symptoms. Especially, metoprolol (lipophilic beta blocker) 
and atorvastatin (statin) appear to increase the risk of depression 
according to a few recent studies [3]. Few studies were investigated that 
the effects of statins specifically on mood have reported mixed findings, 
with some suggesting an increased risk of depression, while others have 
found either no association between statin use and mood disturbances or 
that statins, in fact, may protect against the risk of depression [3,4]. Beta-
blockers or statins are chief support of CVD. With depression associated 
independently with CVD, metoprolol, and statin; it is expected to have a 
larger impact on patients with all three risk factors. We decided to study 
this prevalence, in a corporate hospital in Hyderabad as data regarding 
the same is lacking [4,5].
Link between beta-blockers and depression
First reported in the 1960s, beta-blocker induced depression was 
thought to result from the drugs’ antagonistic effect on norepinephrine 
at β1 post-synaptic brain receptors [6]. A meta-analysis examined 15 
randomized, controlled studies involving 35,000 subjects taking beta-
blockers for the treatment of myocardial infarction, heart failure, or 
hypertension, and demonstrated no statistical difference between 
beta-blockers and placebo with respect to depression, although beta-
blockers were associated with increased incidence of fatigue and sexual 
dysfunction. The absolute incidence of depressive symptoms was 6/1000 
subjects. The authors concluded that it is important to distinguish fatigue 
from depression that a temporal association between beta-blocker use 
and depression does not seem to exist (up to 12 months) [7,8].
Possible link between statins and depression
It is suspected that hundreds of cases of statin-associated hostility, 
aggression, irritability, paranoia, homicidal ideation, depression, and 
suicide are somehow linked to dolichols and altered cell messaging. 
The main function of dolichol (dolichyl phosphate) is its participation in 
glycoprotein synthesis, and this lipid probably has no other major role 
in cellular processes [3]. The decrease in the levels of dolichols or its 
inhibition in the downstream of the mevalonate pathway may possibly 
cause depression [9-11].
Objectives
The objective of the study is to assess the prevalence of depression in 
cardiac patients. The secondary objective of the study is as follows:
• To assess the severity of CVD and depression among men and women.
• To assess the depression in patients using beta-blockers and statins 
concomitantly.
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
org/licenses/by/4. 0/) DOI: http://dx.doi.org/10.22159/ajpcr.2018.v11i12.28444
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• To assess the depression in patients using only beta-blockers.
• To assess the depression in patients using only statins.
METHODS
Study protocol
It is a prospective study conducted for a period of 6 months and about 
250 patients, met the study criteria were included in the study. The 
required data are collected from the patients through direct interview using 
standard questionnaires and also from patients’ respective case sheets. The 
acquired data are evaluated based on the respective questionnaire scales 
and are used to measure the severity of depression in cardiac patients.[12-14]
Study site
The study was conducted at a corporate hospital in the city of 
Hyderabad, Telangana, India.
Study design
It is a prospective observational study, wherein standard questionnaire 
tools, i.e., Patient Health Questionnaire-9 (PHQ-9) and BDI-II are used 
to diagnose the severity of depression in cardiac patients.[15,16]
Study period
The study period was 6 months (5 months follow-up period).
Study population
A total of 250 patients are included in the study, of which 150 patients 




• All the patients above the age of 16 years are included in the study.
• All male and female patients, including pregnant women with 
cardiac diseases, who are able to answer the given questionnaires 
are included.
Exclusion criteria
The following criteria were excluded from the study:
• Patients below the age of 16 years.
• Patients without any cardiac complications.
• Disabled and mentally challenged individuals with or without cardiac 
complications (who cannot answer the questionnaire).
Two standard questionnaires are taken into consideration to assess 
depression in cardiac patients which are listed as below.
PHQ-9
The PHQ-9 is a multipurpose instrument for screening, diagnosing, 
monitoring, and measuring the severity of depression. This is a nine-
item questionnaire which helps both to diagnose depression and assess 
severity Table 1.
Beck Depression Inventory-second edition (BDI-II)
Is a 21-question multiple choice self-report inventory, one of the most 
widely used psychometric tests for measuring the severity of depression.
Interpreting the BDI-II
Add up the score for each of the 21 questions by counting the number to 
the right of each question you marked Table 2.
RESULTS AND DISCUSSION
Prevalence of depression in cardiac patients
• Prevalence of minor to major depressive symptoms according to 
BDI-II was found to be 17.2%.
• Prevalence of minor to major depressive symptoms according to 
PHQ-9 was found to be 19.2%.
• Among male patients, 13% showed depressive symptoms, whereas 
among female patients, 25% showed depressive symptoms.
Distribution based on BDI-II scores
A total of 250 cardiac patients were screened for depression using BDI-II and 
PHQ-9. According to BDI-II scores, of 250 patients, 68% were normal, 15% 
showed mild mood disturbances, 9% had borderline clinical depression, 
6% were moderately depressed, and 2% suffered from severe depression. 
Prevalence of borderline to severe depression in cardiac patients according 
to the BDI-II scores was found to be 17% as shown in Fig. 1.
Distribution based PHQ-9 scores
According to PHQ-9 scores, of 250, 46 were normal, 34% showed 
minimal symptoms, 13% had mild depression, 6% were moderately 
Fig. 1: Distribution based on levels of depression according to the 
Beck Depression Inventory-II scores
Fig. 2: Distribution based on levels of depression according to 
Patient Health Questionnaire-9 scores
Fig. 3: Distribution of patients using beta-blockers plus statins 
based on Beck Depression Inventory-II scores
Fig. 4: Distribution of patients using beta-blockers plus statins 
based on the Patient Health Questionnaire-9 scores
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depressed, and 1% was found to have major depression. Prevalence of 
mild to major depression in cardiac patients according to PHQ-9 scores 
was found to be 20% as shown in Fig. 2.
Distribution based on beta-blockers and statins use
Of 250 patients 159 used beta-blockers plus statins concomitantly. From 
the time of visit to the second follow-up, the number of patients suffering 
from depression increased. It is clear from the graph that the number 
of patients who were normal at the visit decreased from 111 at visit to 
93 on second follow-up (after 2 months). Number of people with mood 
disturbances increased, this may be a sign that the condition may further 
lead to an increase in the severity of depressive symptoms. For patients 
with moderate depression, the number has increased from 5 patients at 
visit to 15 patients on the second follow-up as shown in Fig. 3.
According to PHQ-9 scores, number patients with minimal to moderate 
depression are highest during the first follow-up. Number of patients 
with major depression has doubled from the time of the visit to the 
second follow-up as shown in Fig. 4.
Prevalence of minor to major depression among the patients using 
beta-blockers plus statins
Among the patients coadministering beta-blockers and statins, 15% 
were depressed according to BDI-II, and 16% were depressed according 
to PHQ-9 at visit. After 1 month (first follow-up), the percentage 
increased by 8% (for BDI-II)-12% (for PHQ-9) and remains almost the 
same at the second follow-up (Fig. 5).
Distribution of patients based on beta-blockers use
A total of 26 patients used only beta-blockers. Among these patients 
15 patients were normal, patients with mood disturbances increased 
from 5 patients at visit to 10 patients during the second follow-up. 
There was a decrease in a number of patients with mild to moderate 
depression from the time of visit to second follow-up as shown in Fig. 6.
According to PHQ-9 scores, in patients using only beta-blockers, 
there was a decrease in the number of patients with minor to major 
depression from the time of visit to second follow-up as shown in Fig. 7.
Comparison of BDI-II and PHQ-9 scores in the patients using 
beta-blockers
As per BDI-II and PHQ-9 scores, the percentage of patients with minor 
to major depression among the patients using only beta-blockers 
decreased significantly from the time of visit to the second follow-up 
as shown in Fig. 8.
Percentage of patients with minor to major depression based on 
the beta-blocker used
Prevalence of depression in patients using metoprolol has increased 
from the time of visit to first follow-up and decreased again in the 
second follow-up, while in carvedilol users it was a quiet contrast 
scenario with decreased prevalence of depressive symptoms at first 
Fig. 5: Percentage of patients with minor to major depression 
among the patients using beta-blockers plus statins
Fig. 6: Distribution of patients using only beta-blockers based on 
the Beck Depression Inventory-II scores
Fig. 7: Distribution of patients using only Beta-blockers based on 
the Patient Health Questionnaire-9 scores
Fig. 9: Percentage of patients with minor to major depression 
based on the beta-blocker used
Fig. 10: Distribution of patients using only statins based on the 
Beck Depression Inventory-II scores
Fig. 8: Comparison of Beck Depression Inventory-II and Patient 
Health Questionnaire-9 scores in the patients using beta-blockers
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follow-up and a steep rise in prevalence was observed at the second 
follow-up as shown in Fig. 9.
Distribution based on statins use
A total of 43 patients used only statins. According to the BDI-II scores, in 
patients using only statins, there was no significant difference between 
the number of patients with moderate to severe depression from the 
time of visit to second follow-up. However, there was a slight increase in 
number patients with borderline clinical depression or mild depression 
from visit to second follow-up as shown in Fig. 10.
There was an increase in moderate - major depression from the time of 
visit to the second follow-up, whereas number of patients with minimal 
symptoms and mild depression decreased from the time of visit to the 
second follow-up as shown in Fig. 11.
Comparison of BDI-II and PHQ-9 score in the patients using only 
statins
The percentage of patients with minor to major depression among the 
patients using only statins increased significantly from the time of visit 
to second follow-up as shown in Fig. 12.
Distribution based on the type of statins
From the time of the visit to the second follow-up, the percentage 
of patients with depression has increased from 16.6% to 22.7% 
according to BDI-II score in case of atorvastatin users and 12.1–15.60% 
according to PHQ-9 score in case of rosuvastatin users. It is clear that 
the prevalence of depression in atorvastatin users is higher than that of 
rosuvastatin users as shown in Fig. 13.
Screening for depression was done using the two standard questionnaires. 
Throughout the study period, on an average 17.2% of the whole study 
population were found to exhibit symptoms of depression based on 
BDI-II score. In accordance with the PHQ-9 scores, 19.2% of total study 
population exhibited minor to major depression. Almost about 3/4th of 
the population (i.e. ,73%) hold to be males, and the rest 1/4th (i.e., 27%) 
were females. Therefore, it’s a clear indication that males are more 
affected by cardiovascular diseases as compared to females. The reason 
for this might be several lifestyle factors that differ in men and women. 
Smoking has been the paramount risk factor for CVD and men are more 
prone to the habit of smoking than women, in a country like India. This 
might be one of the reasons why the study showed that a high percentage 
of men with coronary artery disease. Hence, it is assumed that exposure 
to endogenous estrogens during the fertile period of life delays the 
manifestation of atherosclerotic disease in women.
Depression is approximately twice as prevalent among women as it is 
among men. The results in the present study show that on an average 
23 of 68 females (33%) and 42 of 182 males (23%) have observed to 
have minor-major depression (BDI-II score >16; PHQ-9 score >9). Thus, 
it conveys that females are 1.5 times more affected with depression 
than males. Many have attributed this disparity to the various stresses 
women face as a result of their gender and the demands women 
confront as they occupy multiple and often conflicting roles within the 
family, in the community, and at work.
Our study predicates that concomitant use of beta-blockers and statins 
may increase the chances of having depression. Although no evidence of 
such interaction has been mentioned in previous studies, the statement 
is completely contingent on our observations in the study population. 
Further, studies in this aspect may provide us with better evidence.
Patients using beta-blockers experienced a reduction in depression 
during the course of the study, but most of them had mild mood 
disturbances after a 3 month follow-up. In connection to the above 
observations, statins might not show a greater degree of variability 
in psychological aspects of a patient. Yet, slight increase in depressive 
symptoms seems to occur with statin use which may often be overlooked. 
A pile of studies were done by researchers in relation to this facet but 
failed to establish a clear association between statins and depression. 
Researchers have put forth number of hypotheses; one such hypothesis 
affirms that depression in patients using beta-blockers may be due 
to the cholesterol-lowering effect of statins in brain. Individuals who 
take statins to lower their cholesterol sometimes display symptoms of 
irritability, anxiety, and depression; these symptoms are reported by 
their family members, caregivers, and coworkers.
CONCLUSION
• Prevalence of minor to major depression according to BDI-II was 
found to be 17%.
• Prevalence of minor to major depression according to PHQ-9 was 
found to be 20%.
• Cardiovascular diseases have been more prevalent in men than in 
women whereas depressive symptoms have been more prevalent in 
women than in men.
• Use of beta-blockers and statins concomitantly may lead to a slight 
increase in depressive symptoms. Therefore, in patients who are on 
both the medications, there is a need for screening of depressive 
symptoms and monitor the patients’ status from time to time.
• The study reveals that the use of beta-blockers is not associated 
with an increase in depression. In fact, it has shown to decrease 
the symptoms of depression in cardiac patients who were on beta-
blocker therapy.
Fig. 11: Distribution of patients using only statins based on the 
Patient Health Questionnaire-9 scores
Fig. 12: Comparison of Beck Depression Inventory-II and Patient 
Health Questionnaire-9 score in the patients using only statins 
Fig. 13: Percentage of patients with minor to major depression 
based on the statins used
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• Use of statins was observed to increase the chances of depression 
slightly which is often neglected as the symptoms may not be severe 
and may be often under-diagnosed.
• Atorvastatin was associated with a higher level of depression when 
compared to Rosuvastatin.
• Screening of the depression in cardiovascular patients should be 
made obligatory as its prevalence is significant.
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Table 1: PHQ-9 score scale
PHQ-9 score Provisional diagnosis Treatment 
recommendation patient 
preferences should be 
considered
5–9 Minimal symptoms Support, educate to call if 
worse, return in 1 month






and antidepressant or 
psychotherapy








if not improved on 
monotherapy)
PHQ-9: Patient Health Questionnaire-9
Table 2: Level of depression
Total score Level of depression
0–10 Normal
11–16 Mild mood disturbance
17–20 Borderline clinical depression
21–30 Moderate depression
31–40 Severe depression
>40 Extreme depression
